Zinc Carnosine-based Modified Bismuth Quadruple Therapy versus Standard Triple Therapy for Helicobacter pylori Eradication: a prospective open-label randomized study

Nour Ibrahim

3 hours ago

3,027 1 minute read

Poster Name: Nour Ibrahim
Category: (Speaker/Oral Presentation)

Nour Ibrahim, Hassan Al Said, Ali Choukair

Global Journal of Gastroenterology & Hepatology Research [GJGHR]

Abstract

Introduction: Helicobacter pylori infection is a worldwide problem with increasing burden on
the health sector due to its increasing rate of resistance. The conventional triple therapy is
becoming obsolete with a high failure rate of eradication, necessitating the need for better
alternatives or regimens.

Methods: Ninety-two patients with dyspepsia symptoms and positive 13C-urea breath test were
randomly assigned in to two groups. The first group (control group) was treated for 14 days
using standard triple therapy (TT) protocol: esomeprazole (40 mg twice daily), amoxicillin (1 g
twice daily) and clarithromycin (500 mg twice daily). On the other hand, the second group were
prescribed a 10-day course of modified bismuth quadruple therapy (MBQT) fortified with zinc
carnosine: TT in addition to bismuth subcitrate (240 mg twice daily) and zinc carnosine (75 mg
twice daily). A repeated 13C-urea breath test was done 4 weeks after the completion of the
eradication therapy.

Results: There were no demographic differences between the two groups. The eradication rate
was 93.5% (43/46) in the MBQT group compared to 69.6% (32/46) in the TT group (P = 0.003).
Besides dizziness, which was recorded in MBQT group, there were no significant differences in
side effects between the two groups.

Conclusion: 10 days of modified bismuth quadruple therapy fortified with zinc carnosine is
superior to 14 days of conventional triple therapy in eradicating Helicobacter pylori infection,
with no additional significant adverse events.

Tags